Brain metastases in patients with non-small cell lung cancer: Focus on the role of chemotherapy

Annals of Oncology

Volumn 17, Issue SUPPL. 2, 2006, Pages

  Adamo, V ^a   Franchina, T ^a   Adamo, B ^a   Scandurra, G ^a   Scimone, A ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CELECOXIB; CISPLATIN; ETOPOSIDE; FOTEMUSTINE; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; TEMOZOLOMIDE; TENIPOSIDE; THALIDOMIDE; TOPOTECAN;

AGE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BRACHYTHERAPY; BRAIN METASTASIS; BRAIN RADIATION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LIFE EXPECTANCY; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RADIOSURGERY; STEREOTAXIC SURGERY; SURVIVAL RATE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MEDICAL ONCOLOGY; PROGNOSIS; PROTEIN KINASE INHIBITORS;

EID: 33645828643     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj930     Document Type: Article

References (31)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics. CA Cancer J Clin 2003; 53: 5-26.
2. Roggero E, Busi G, Palumbo A, Pedrazzini A. Gefinitib ('Iressa', ZD1839) is active against brain metastases in a 77 year old patient. J Neurooncol 2005 Feb; 71(3): 277-280.
3. Wen PY, McLaren Black P, Laeffler JS. Metastatic brain cancer. In De Vita Vi Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, 6th edn. Philadelphia, PA: Lippincott Williams and Wilkins 1999; 2655-2670.
4. Langer CJ and Mehta MP. Current management of brain metastases, with a focus on systemic options. J Clin Oncol 2005 Sep 1; 23(25).
5. Taimur S, Edelman MJ. Treatment options for brain metastases in patients with non-small cell lung cancer. Curr Treat Options Oncol 2003 Feb; 4(1): 89-95.
6. Peereboom DM. Chemotherapy in brain metastases. Neurosurgery. 2005 Nov; 57 (5 Suppl): S54-65.
7. Soffietti R, Costanza A, Laguzzi E et al. Radiotherapy and chemotherapy of brain metastases. J Neurooncol 2005 Oct; 75(1): 31-42.
8. Tosoni A, Ermani M, Brandes AA. The pathogenesis and treatment of brain metastases: A comprehensive review. Crit Rev Oncol Hematol 2004; 52: 199-215.
9. Katz A and Zalewski P. Quality-of-life benefits and evidence of antitumours activity for patients with brain metastases treated with gefitinib. Br J Cancer 2003 Dec; 89 (Suppl 2): S15-8.
10. Kleisbauer JP, Guerin JC, Arnaud A, Poirier R, Vesco D. Chemotherapy with high-dose cisplatin in brain metastasis of lung cancers. Bull Cancer 1990; 77(7): 661-665.
11. Boogerd W, van der Sande JJ, van Zandwijk N. Teniposide sometimes effective in brain metastases from non-small cell lung cancer. J Neurooncol 1999 Feb; 41(3): 285-289.
12. Ebert BL, Niemierko E, Shaffer K, Salgia R. Use of Temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer. Oncologist 2003; 8(1): 69-75.
13. Pujol JL, Monnier A, Berille J et al. Phase II study of nitrosourea fotemustine as single-drug chemotherapy in poor-prognosis non-small-cell lung cancer. Br J Cancer 1994 Jun; 69(6): 1136-1140.
14. Hedde JP, Ko Y, Metzler U et al. A phase I/II trial of topotecan and radiation therapy for CNS-metastases of patients with solid tumors. Proc Am Soc Clin Oncol 2003; 22: 111 (Abstr 444).
15. Abrey LE, Olson JD, Raizer JJ, Mack M, Rodavitch A, Boutros DY. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neuro-Oncol 2001; 53: 259-265.
16. Christodoulou C, Bafaloukos D, Kosmidis P et al. for the Hellenic Cooperative Oncology Group: Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 2001; 12: 249-254.
17. Dziadziuszko C, Ardizzoni A, Postmus PE et al. on behalf of the EORTC Lung Cancer Group: Temozolomide in patients with advanced non-small-cell lung cancer with and without brain metastases: A phase II study of the EORTIC Lung Cancer Group (08965). Eur J Cancer 2003; 39: 1271-1276.
18. Friedman HS, Evans B, Reardon D et al. Phase II trial of temozolomide for patients with progressive brain metastases. Proc Am Soc Clin Oncol 2003; 22: 102 (Abstr 408).
19. Siena S, Landonio G, Baietta E et al. Multicenter phase II study of temozolomide therapy for brain metastasis in patients with malignant melanoma, breast cancer, and non-small cell lung cancer. Proc Am Soc Clin Oncol 2003; 22: 102 (Abstr 407).
20. Antonadou D, Coliarakis N, Paraskevaidis M et al. Whole brain radiotherapy alone or in combination with temozolomide for brain metastases: A phase III study. Proceedings from the 2002 Annual Meeting of the American Society for Theraupetic Radiology and Oncology (ASTRO). Int J Radiat Oncol Biol Phys 2002; 54: 93-94.
21. Cortes J, Rodriguez J, Aramendia JM et al. Front-line paclitaxel/ cisplatin based chemotherapy in brain metastases from non-small cell lung cancer. Oncology 2003; 64: 28-35.
22. Kaba SE, Kyritsis AP, Hess K et al. TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors. J Clin Oncol 1997; 15: 1063-1070.
23. Malacarne P, Santini A, Maestri A: Response of brain metastases from lung cancer to systemic chemotherapy with carboplatin and etoposide. Oncology 1996; 53: 210-213.
24. Franciosi V, Cocconi G, Michiara M et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, non small cell lung carcinoma or malignant melanoma. Cancer 1999; 85: 1599-1605.
25. Minotti V, Crino L, Meacci ML et al. Chemotherapy with cisplatin and teniposide for cerebral system metastases from non-small cell lung cancer. Lung Cancer 1998; 20: 93-98.
26. Cotto C, Berille J, Souquet PJ et al. A phase II trial of fotemustine and cisplatin in central nervous system metastases from non-small cell lung cancer. Eur J Cancer 1996; 32A: 69-71.
27. Cappuzzo F, Calandri C, Bartolini S, Crino L. ZD 1839 in patients with brain metastases from non-small cell lung cancer (NSCLC): Report of four cases. Br J Cancer 2003; 89: 246-247.
28. Ceresoli GL, Gregorc V, Cappuzzo F, Spreafico A, Bencardino KB, Lombardo L, Schipani S, Cozzarini C, Crino L, Villa E. ZD 1839 in non-small cell lung cancer (NSCLC) patients with brain metastases (BM). Proc Am Soc Clin Oncol 2003; 22: 674 (Abstr 2709).
29. Fujiwara K, Kiura K, Ueoka H, Tabata M, Hamasaki S, Tanimoto M. Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status. Lung Cancer 2003; 40: 73-76.
30. Stemmler HJ, Weigert O, Krych M, Schoenberg SO, Ostermann H, Hiddemann W. Brain metastases in metastatic non-small cell lung cancer responding to single-agent gefitinib: A case report. Anticancer Drugs 2005; 16(7): 747-749.
31. Hada M, Horiuchi T. A case report of chemotherapy with thalidomide, celecoxib and gemcitabine in the treatment of patients with brain metastases from lung cancer. No Shinkei Geka 2005; 10: 1021-1026.